Business
Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance
NEW YORK, February 03, 2026--PFE Q4 2025 Earnings Release
About this update from Pfizer, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":212,"url":"https://media.zenfs.com/en/business-wire.com/8a7baf4c0dffff29ec99d62e26d096eb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/uAakSXlIYHskgIAgvEt3Sw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQyNDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/8a7baf4c0dffff29ec99d62e26d096eb","width":480,"height":212}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Focused Execution Drives Strong Full-Year 2025 EPS Performance","length":62,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Enters 2026 with Clear Strategic Priorities and Growing Late-Stage Pipeline","length":75,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Advanced 11 Key Pivotal Study Starts in 2025 and ~20 Key Pivotal Study Starts Planned for 2026","length":94,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":231,"olType":false},{"type":"text","content":"NEW YORK, February 03, 2026--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter and full-year 2025 and reaffirmed its full-year 2026 financial guidance(1) provided on December 16, 2025.","length":221,"tagName":"p"},{"type":"text","content":"EXECUTIVE COMMENTARY","length":20,"tagName":"p"},{"type":"text","content":"Dr. Albert Bourla, Chairman and CEO of Pfizer:","length":46,"tagName":"p"},{"type":"text","content":""With excellent execution in 2025, we delivered a solid financial performance and strengthened Pfizer’s foundation for future growth. Looking ahead, 2026 will be an important year rich in key catalysts, including our expectation for approximately 20 key pivotal study starts, and continued strategic investment to maximize our opportunities for industry-leading growth at the end of the decade."","length":405,"tagName":"p","attribs":{}},{"type":"text","content":"David Denton, CFO and EVP of Pfizer:","length":36,"tagName":"p"},{"type":"text","content":""I’m pleased with our solid financial results in 2025. With focused commercial execution, we delivered full-year operational revenue growth of 6% for our non-COVID portfolio, and our continued financial discipline drove strong EPS performance. Today, we are reaffirming our full-year 202...